Aditya Bardia, MDEnriched profile
Professor of Medicine; Program Director, Breast Medical Oncology; Assistant Chief (Translational Research), Division of Hematology-Oncology; Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center · Amyotrophic Lateral Sclerosis Therapy Development Institute
Overview
Updated 14 Jul 2026
Aditya Bardia is Professor of Medicine at David Geffen School of Medicine at UCLA / UCLA Health Jonsson Comprehensive Cancer Center. The public record shows 1,145 publications with 39,602 citations (h-index 90), centered on Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics. It also documents an investigator role on 3 registered clinical trials.
- Most recent indexed publication: 2026 · Nature nanotechnology
- Top research focus: Advanced Breast Cancer Therapies
- 3 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 65 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 319.
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Sponsor: Marengo Therapeutics, Inc.
InvestigatorPhase 1/PHASE2RecruitingNCT06827613 - A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Sponsor: Stemline Therapeutics, Inc.
InvestigatorPhase 1RecruitingNCT06638307 - Fulvestrant + Neratinib In Breast Cancer
Sponsor: Massachusetts General Hospital
InvestigatorPhase 2WithdrawnNCT04901299
Industry payments
26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Activating a B cell immune response regresses immunologically cold tumours.
Nature nanotechnology
2026 - ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.
Nature communications
2026 - Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.
Clinical cancer research
2026
Most-cited worksby citation count (OpenAlex)
- 01
- 02
- 03Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study1,802 citations2020
- 04Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer1,551 citations2021
- 05
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Internal Medicine Residency
Mayo Clinic College of Medicine and Science, Rochester, MN
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Medical Oncology & Hematology Fellowship
Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Editorial board member
The Oncologist, Therapeutic Advances in Medical Oncology, and NPJ Precision Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliationsappointments beyond the home institution
- Previously Director of Breast Cancer Research
Massachusetts General Hospital Cancer Center (2021-2023), and faculty at Harvard Medical School
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →audiomedica.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Breastcancer.org podcast appearances
e.g. "Enhertu, HER2-Low, and -Ultralow Metastatic Breast Cancer" and "Experimental Elacestrant"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breastcancer.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/aditya-bardia-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/aditya-bardia-a1239b5a
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Aditya-Bardia-42468506
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Other
videopodcast.researchtopractice.com/breast-cancer-aditya-bardia-md-mph
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →videopodcast.researchtopractice.com ↗ - Other
bcrf.org/researchers/aditya-bardia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗ - Other
breastcancer.org/podcast/enhertu-her2-low-ultralow-breast-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breastcancer.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
- 1,905
- publications
- 187
- h-index
- 1
- trial
Eric Winer, MD
Yale Cancer Center
- 1,624
- publications
- 171
- h-index
- 20
- trials
Hope Rugo, MD
City of Hope
- 1,607
- publications
- 140
- h-index
- 30
- trials
Lajos Pusztai, MD
Yale University
- 1,394
- publications
- 114
- h-index
- 13
- trials